Claimed effect · CJC-1295

Does CJC-1295 help with any clinical outcome?

D
Grade D — no human evidenceNone · effect size: not measurable
Short answerNo human evidence. As of 2 September 2026, only none exist for CJC-1295 for any clinical outcome. The programme was discontinued before efficacy trials in any indication.

What the studies show

The programme was discontinued before efficacy trials in any indication.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

In context

CJC-1295 is a modified growth-hormone-releasing hormone fragment engineered to bind albumin so that it lasts days rather than minutes. Early human trials showed substantial, sustained rises in growth hormone and IGF-1 with weekly dosing. Development was discontinued and no trial has measured whether that translates into any clinical outcome. It is not approved anywhere and is banned in sport.

CJC-1295 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is CJC-1295 proven to help with any clinical outcome?
No. There is no human evidence for it (None); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
The programme was discontinued before efficacy trials in any indication.
Is CJC-1295 approved for this?
No. CJC-1295 is not approved; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for CJC-1295

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →